BIOTRONIK's Ultrathin Strut Orsiro Coronary Drug-Eluting Stent Continues to Deliver Excellent Results After Three Years

Data from BIOFLOW-V Trial Presented at CRT and Published in JACC: Cardiovascular Interventions Reinforces Orsiro's Ability to Outperform Abbott's Xience

NATIONAL HARBOR, Md., Feb. 24, 2020 /PRNewswire/ -- BIOTRONIK today announced three-year data from the BIOFLOW-V trial, which was presented yesterday at the 2020 CRT Congress. The three-year follow-up data demonstrates consistently lower clinical event rates and improvement in patient outcomes, reinforcing the differentiation of the Orsiro® coronary drug-eluting stent (DES) – the first and only ultrathin strut DES to outperform Xience.1,2 Orsiro received FDA approval in 2019 and has been used to treat more than two million patients worldwide to date. The study results have been simultaneously published in JACC: Cardiovascular Interventions.

The three-year results show Orsiro’s ability to outperform Xience, long considered the benchmark for clinical performance, across the most important three-year secondary endpoints of BIOFLOW-V. Reference: Kandzari D et al. J Am Coll Cardiol. Cardiovasc Interven. 2020, doi: 10.1016/j.jcin.2020.02.019.

Orsiro's clinical performance in the pivotal BIOFLOW-V trial demonstrated significantly lower rates for target lesion failure (TLF) and target vessel myocardial infarction (MI) at 12 months in comparison to Xience in a large, complex patient population (n=1,334).2 At two years, treatment with Orsiro further improved event rates in comparison to Xience, including a significant reduction in target lesion revascularization (TLR) and spontaneous MI.3

The three-year results show Orsiro's ability to outperform Xience, long considered the benchmark for clinical performance, across the most important three-year secondary endpoints of BIOFLOW-V4:

  • 40% lower TLF rate in favor of Orsiro (8.6% versus 14.4% TLF rate, p=0.003)
  • a 52% lower ischemia-driven TLR rate (3.4% versus 6.9%, p=0.008)
  • a 46% lower rate of TV-MI (5.5% versus 10.1%, p=0.004)
  • a 90% lower late/very late definite/probable stent thrombosis (ST) rate (0.1% vs. 1.2%, p=0.018)

"Orsiro sets a new standard for safety and efficacy in long-term clinical endpoints, including statistically lower target lesion revascularization and target vessel MI rates," said Dr. David Kandzari, BIOFLOW-V US principal investigator, Piedmont Heart Institute, Atlanta, Georgia. "BIOFLOW-V data are the best clinical outcomes observed among comparative clinical trials with contemporary DES. It was widely believed that safety and efficacy with DES had plateaued, but Orsiro has surpassed the limits. Year after year the results have been impressive."

The Orsiro cobalt chromium metal stent elutes sirolimus via BIOlute, BIOTRONIK's bioabsorbable polymer coating. Beneath the bioabsorbable layer is BIOTRONIK's proBIO coating, a silicon carbide layer covering the bare metal surface and designed to reduce nickel ion release. The Orsiro stent system provides ultrathin stent struts without compromising radial strength and a low crossing profile for easier lesion cross in complex PCI.5  

"Orsiro's consistently better long-term outcomes completely alter the dynamic of what had become a highly commoditized DES market," said Ryan Walters, President at BIOTRONIK, Inc. "We designed Orsiro with a focus on efficacy, even in challenging cases. Hospital administrators have the option to choose a DES that shows improved clinical event rates, and interventionalists can rely on Orsiro's deliverability to treat complex lesions6 and challenging subgroups to achieve outstanding patient outcomes. Orsiro is proving to be exactly what physicians need for best-in-class performance and what patients deserve."

Orsiro, BIOlute and proBIO are trademarks or registered trademarks of the BIOTRONIK Group of Companies.

References:
1 Xience is a trademark or registered trademark of the Abbott Group of Companies.
2 Kandzari D et al. The Lancet. 2017, 390(10105).
3 Kandzari D et al. Journal of the American College of Cardiology. 2018, 72(25).
4 Kandzari D et al. J Am Coll Cardiol. Cardiovasc Interven. 2020, doi: 10.1016/j.jcin.2020.02.019. 
5 BIOTRONIK data on file.
6 Orsiro is indicated for improving coronary luminal diameter in patients, including those with diabetes mellitus, with symptomatic heart disease, stable angina, unstable angina, non-ST elevation myocardial infarction or documented silent ischemia due to atherosclerotic lesions in the native coronary arteries with a reference vessel diameter of 2.25 mm to 4.0 mm and a lesion length of ≤ 36 mm.

For more information, visit:
www.biotronik.com

About BIOTRONIK:
BIOTRONIK is a leading medical device company that has been developing trusted and innovative cardiovascular and endovascular solutions for more than 50 years. Driven by a purpose to perfectly match technology with the human body, BIOTRONIK innovations deliver care that saves and improves the lives of millions diagnosed with heart and blood vessel diseases every year. BIOTRONIK is headquartered in Berlin, Germany, and represented in over 100 countries.

Follow us on:

 

BIOTRONIK is a leader in cardio- and endovascular medical technology. Several million patients have received BIOTRONIK implants designed to save and improve the quality of their lives, or have been treated with BIOTRONIK coronary and peripheral vascular intervention products. (PRNewsFoto/BIOTRONIK)
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/biotroniks-ultrathin-strut-orsiro-coronary-drug-eluting-stent-continues-to-deliver-excellent-results-after-three-years-301009894.html

SOURCE BIOTRONIK